FSC/ETI repeal
This article was originally published in The Rose Sheet
Executive Summary
Conference report approved by U.S. House and Senate negotiators Oct. 6 would end retaliatory sanctions against the U.S. by Europe, including those on select cosmetic and fragrance ingredients. Report calls for repeal of the U.S. Foreign Sales Corporation/Extraterritorial Income Exclusion Subsidy, which allowed a portion of U.S. companies' income generated outside the U.S. to be exempt from taxes, and replace it with more than $8 bil. of transition relief over three years, House Committee on Ways and Means says. Presented by committee Chairman Bill Thomas (R-Calif.), the report still needs approval from full House and Senate. World Trade Organization gave the European Union the green light to impose tariffs on certain U.S. products, and in March, the EU announced it would impose a 5% customs duty on them (1"The Rose Sheet" March 8, 2004, In Brief)...
You may also be interested in...
EU trade duties
European Union initiates customs duty of 5% on list of U.S. products including select cosmetic and fragrance ingredients March 1 in response to World Trade Organization dispute regarding the U.S. Foreign Sales Corporations subsidy. Countermeasures will include automatic monthly increases by 1% up to a ceiling of 17% on March 1, 2005, unless the U.S. subsidy is repealed, the EU says. Draft proposal of the EU sanctions list originally included 11 cosmetic ingredient categories, but the final list, approved by the WTO last year, comprised a very limited number of cosmetic ingredients, including deterpenated oils derived from clove, niaouli and ylang-ylang and non-deterpenated oils from lavender (1"The Rose Sheet" May 12, 2003, p. 12)...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.